Factor XII-dependent fibrinolysis: a double function of plasma kallikrein and the occurrence of a previously undescribed factor XII- and kallikrein-dependent plasminogen proactivator. 1979

C Kluft, and M M Trumpi-Kalshoven, and A F Jie, and E C Veldhuyzen-Stolk

Fibrinolytic studies in euglobulin fractions of Fletcher trait plasma (deficient in prekallikrein) revealed reduced activities as compared to normal plasma. A quantitative assay for total plasminogen activator plus proactivator in plasma showed that the amount in Fletcher trait patients is about half of normal (normal = +/- 100 blood activator units [BAU]/ml). Plasma kallikrein partially purified in a high and low molecular weight form exerted plasminogen activator activity amounting to 10-15 BAU/ml plasma. So, the absence of kallikrein in the deficient plasma cannot fully account for the reduction in activator activity. Additions of kallikrein preparations or normal plasma fractions resulted in additional activator activity in Fletcher trait plasma which was assessed at 30-40 BAU/ml. This activity was assumed to originate from a previously undescribed plasminogen proactivator whose activation is kallikrein- and factor XII-dependent. Fractionation experiments demonstrated the presence of two major activities and a minor activity caused by kallikrein in normal plasma. It is concluded that plasma kallikrein has two functions in the generation of factor XII-dependent fibrinolytic activity: one as a direct plasminogen activator and another as a factor in the activation of a major factor XII-dependent plasminogen proactivator.

UI MeSH Term Description Entries
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D011288 Prekallikrein A plasma protein which is the precursor of kallikrein. Plasma that is deficient in prekallikrein has been found to be abnormal in thromboplastin formation, kinin generation, evolution of a permeability globulin, and plasmin formation. The absence of prekallikrein in plasma leads to Fletcher factor deficiency, a congenital disease. Fletcher Factor,Plasma Prokallikrein,Kallikreinogen,Plasma Prokallikrein A,Factor, Fletcher,Prokallikrein A, Plasma,Prokallikrein, Plasma
D005174 Factor XII Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor XII to XIIa. Deficiency of factor XII, also called the Hageman trait, leads to increased incidence of thromboembolic disease. Mutations in the gene for factor XII that appear to increase factor XII amidolytic activity are associated with HEREDITARY ANGIOEDEMA TYPE III. Coagulation Factor XII,Hageman Factor,Factor 12,Factor Twelve
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012712 Serum Globulins All blood proteins except albumin ( Euglobulin,Euglobulins,Pseudoglobulin,Pseudoglobulins,Serum Globulin,Globulin, Serum,Globulins, Serum

Related Publications

C Kluft, and M M Trumpi-Kalshoven, and A F Jie, and E C Veldhuyzen-Stolk
January 1978, The Journal of laboratory and clinical medicine,
C Kluft, and M M Trumpi-Kalshoven, and A F Jie, and E C Veldhuyzen-Stolk
February 1974, Thrombosis research,
C Kluft, and M M Trumpi-Kalshoven, and A F Jie, and E C Veldhuyzen-Stolk
March 1984, The Journal of laboratory and clinical medicine,
C Kluft, and M M Trumpi-Kalshoven, and A F Jie, and E C Veldhuyzen-Stolk
April 1976, Thrombosis research,
C Kluft, and M M Trumpi-Kalshoven, and A F Jie, and E C Veldhuyzen-Stolk
August 2003, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
C Kluft, and M M Trumpi-Kalshoven, and A F Jie, and E C Veldhuyzen-Stolk
November 1982, The Journal of laboratory and clinical medicine,
C Kluft, and M M Trumpi-Kalshoven, and A F Jie, and E C Veldhuyzen-Stolk
March 1972, Nihon seirigaku zasshi. Journal of the Physiological Society of Japan,
C Kluft, and M M Trumpi-Kalshoven, and A F Jie, and E C Veldhuyzen-Stolk
January 1966, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
C Kluft, and M M Trumpi-Kalshoven, and A F Jie, and E C Veldhuyzen-Stolk
April 1980, Biochemistry,
Copied contents to your clipboard!